Ferroptosis and pyroptosis are two forms of cell death that rupture and splash pro-inflammatory cargo onto neighboring cells. Four 2026 studies — spanning skin fibroblasts, brain microglia and neurons, and diabetic kidneys — trace the same self-amplifying loop and identify three brake points: HIF-1α, stem-cell-secreted TSG-6, and puerarin's control of caspase-1.
Mitophagy — the cell's recycling system for damaged mitochondria — slows with age, letting broken units pile up and leak bacterial-like mtDNA that triggers chronic inflammation. Four 2026 studies show restarting this pathway in rheumatoid arthritis and Alzheimer's models suppresses downstream inflammasome activation, while a fourth study reveals selective autophagy extends well beyond mitochondria.
Aging cells leak R-loops and other nucleic acids into the cytoplasm, tripping cGAS-STING and NLRP3 alarms that keep inflammation burning. Three 2026 studies point to the switches and brakes behind inflammaging.
Senescent cells pile up because aging immune systems stop clearing them efficiently. Instead of killing every senescent cell, new 2026 reviews argue for senomorphic strategies that quiet SASP-driven inflammation.
Senescent cells have been the bad neighbor of aging biology for nearly two decades. Three 2026 papers flip the question: before we rush to clear them, do we even know what they are? Turns out we barely did — and now that we're learning, the picture is far less black and white.
A blue pill that might protect your brain, and a fiber classification system that's been misleading you for decades. Two stories about how oversimplified categories can steer us wrong.
Recent large-scale genetic analyses shatter the 'longevity gene' myth: the same genetic variant that lowers mortality in youth can increase risk in old age. From antagonistic pleiotropy to circadian rhythms, hippocampal plasticity, and cross-organ aging axes, unpacking the temporal tug-of-war of aging.
Fifty years of antioxidant trials mostly failed because 85% of mitochondrial DNA damage comes from replication errors, not free radicals. From mitochondrial transplantation and MOTS-c peptide hormones to CoQ10's irreplaceable role in the electron transport chain, aging science is moving from 'slow the damage' to 'replace the parts.
Telomeres are usually cast as the cell's countdown timer that hits zero and you age. But two studies show they manage far more than time: shorten them, and immune cells' mitochondria misfire, inflammation ignites, and cognition takes a causally-linked hit. Telomeres, it turns out, move both inflammation and brainpower.
The brain slows and dulls with age. Could a drug flip a single switch and turn that around? A 2026 review puts its bet on SIRT1, the NAD⁺-dependent enzyme whose depletion in the brain is tied to cognitive decline and dementia. Promising, but still far from a human prescription.